Cogent Biosciences, Inc. (COGT) Financials
COGT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 313.4 million | 55.6 million |
2023-09-30 | 355.4 million | 52.5 million |
2023-06-30 | 392.4 million | 43.9 million |
2023-03-31 | 263.2 million | 39.6 million |
COGT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -44.4 million | 8.9 million |
2023-09-30 | -38.1 million | 8.8 million |
2023-06-30 | -33.3 million | 7.2 million |
2023-03-31 | -40.6 million | 5.9 million |
COGT Net Income
No data available :(
COGT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 265.7 million | - | 18.9 million |
2023-09-30 | 312.8 million | - | 19.2 million |
2023-06-30 | 350.9 million | - | 19.4 million |
2023-03-31 | 220.3 million | - | 19.5 million |
COGT Shares Outstanding
COGT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 315000 | 48.7 million | 9.5 million | - |
2023-09-30 | 121000 | 50.1 million | 9.5 million | - |
2023-06-30 | 1.3 million | 38.9 million | 8.2 million | - |
2023-03-31 | 1.1 million | 36.0 million | 7.2 million | - |
COGT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | 794000 |
2023-09-30 | - | 855000 |
2023-06-30 | - | 1.2 million |
2023-03-31 | - | 723000 |
COGT
Price: $7.53
52 week price:
Earnings Per Share: -2.42 USD
P/E Ratio: -2.44
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 528500
Ebitda: -29.7 millionMarket Capitalization: 726.4 million